Trial Profile
A Phase II, Open-Label, Multi-Center Study to Compare the Pharmacokinetics of Tacrolimus in Stable Pediatric Allograft Recipients Converted From a Prograf Based Immunosuppressive Regimen to a Tacrolimus Prolonged Release, Advagraf Based Immunosuppressive Regimen, Including a Long-Term Follow-Up
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 Dec 2021
Price :
$35
*
At a glance
- Drugs Tacrolimus (Primary) ; Tacrolimus
- Indications Allotransplant rejection
- Focus Pharmacokinetics
- Sponsors Astellas Pharma; Astellas Pharma Europe Ltd
- 04 Dec 2021 This trial has been completed in Poland, as per European Clinical Trials Database.
- 24 Feb 2021 Planned End Date changed from 1 May 2026 to 31 May 2026.
- 06 Jun 2018 Results (n=44) presented at the 2018 American Transplant Congress